×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
XFOR – x4 pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
XFOR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/4
07:25 am
xfor
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference [Yahoo! Finance]
Neutral
Report
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference [Yahoo! Finance]
3/4
07:00 am
xfor
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference
Neutral
Report
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference
3/2
04:30 pm
xfor
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/27
07:22 am
xfor
X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome [Yahoo! Finance]
Medium
Report
X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome [Yahoo! Finance]
2/27
07:13 am
xfor
Norgine welcomes positive CHMP opinion recommending approval of mavorixafor in the European Union for WHIM syndrome [Yahoo! Finance]
Low
Report
Norgine welcomes positive CHMP opinion recommending approval of mavorixafor in the European Union for WHIM syndrome [Yahoo! Finance]
2/27
07:00 am
xfor
X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome
Medium
Report
X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome
2/16
06:07 pm
xfor
X4 Pharmaceuticals, Inc. (XFOR) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript [Seeking Alpha]
Medium
Report
X4 Pharmaceuticals, Inc. (XFOR) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript [Seeking Alpha]
2/3
07:52 am
xfor
X4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026 [Yahoo! Finance]
Low
Report
X4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026 [Yahoo! Finance]
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/17
04:33 pm
xfor
Form SCHEDULE 13G/A X4 Pharmaceuticals, Inc Filed by: BIOTECHNOLOGY VALUE FUND L P
Medium
Report
Form SCHEDULE 13G/A X4 Pharmaceuticals, Inc Filed by: BIOTECHNOLOGY VALUE FUND L P
2/17
04:32 pm
xfor
Form SCHEDULE 13G/A X4 Pharmaceuticals, Inc Filed by: Trails Edge Capital Partners, LP
Medium
Report
Form SCHEDULE 13G/A X4 Pharmaceuticals, Inc Filed by: Trails Edge Capital Partners, LP
2/17
04:31 pm
xfor
Form SCHEDULE 13G/A X4 Pharmaceuticals, Inc Filed by: Bain Capital Life Sciences Fund, L.P.
Medium
Report
Form SCHEDULE 13G/A X4 Pharmaceuticals, Inc Filed by: Bain Capital Life Sciences Fund, L.P.
2/17
02:46 pm
xfor
Form SCHEDULE 13G X4 Pharmaceuticals, Inc Filed by: Saturn V Capital Management LP
Medium
Report
Form SCHEDULE 13G X4 Pharmaceuticals, Inc Filed by: Saturn V Capital Management LP
2/13
05:10 pm
xfor
Form SCHEDULE 13G/A X4 Pharmaceuticals, Inc Filed by: Nantahala Capital Management, LLC
Medium
Report
Form SCHEDULE 13G/A X4 Pharmaceuticals, Inc Filed by: Nantahala Capital Management, LLC
2/12
02:28 pm
xfor
Form SCHEDULE 13G X4 Pharmaceuticals, Inc Filed by: MORGAN STANLEY
Neutral
Report
Form SCHEDULE 13G X4 Pharmaceuticals, Inc Filed by: MORGAN STANLEY
2/5
02:07 pm
xfor
Form SCHEDULE 13G/A X4 Pharmaceuticals, Inc Filed by: FMR LLC
Low
Report
Form SCHEDULE 13G/A X4 Pharmaceuticals, Inc Filed by: FMR LLC
1/15
01:22 pm
xfor
Form SCHEDULE 13G/A X4 Pharmaceuticals, Inc Filed by: Empery Asset Management, LP
Low
Report
Form SCHEDULE 13G/A X4 Pharmaceuticals, Inc Filed by: Empery Asset Management, LP
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/18
X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at ValuEngine from a "buy" rating to a "strong-buy" rating.
33.7%
2/8 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $10.00 price target on the stock. 13.1%
2/14 Form SC 13G/A X4 Pharmaceuticals, Inc Filed by: Cormorant Asset Management, LP 10.5%
4/1 X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 8.4%
7/30 X4 Pharmaceuticals Receives Orphan Drug Designation from European Commission for Mavorixafor for Treatment of WHIM Syndrome 8.2%
6/7 X4 Pharmaceuticals Inc (NASDAQ: XFOR) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating on the stock. 7.5%
4/9 X4 Pharmaceuticals to Present and Participate in the Virtual 19th Annual Needham Healthcare Conference 7.3%
12/23 X4 Pharmaceuticals Inc (NASDAQ: XFOR) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $20.00 price target on the stock. 5.8%
11/10 X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.7%
2/28 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock. 5.3%
2/8 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $10.00 price target on the stock. 13.1%
2/14 Form SC 13G/A X4 Pharmaceuticals, Inc Filed by: Cormorant Asset Management, LP 10.5%
4/1 X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 8.4%
7/30 X4 Pharmaceuticals Receives Orphan Drug Designation from European Commission for Mavorixafor for Treatment of WHIM Syndrome 8.2%
6/7 X4 Pharmaceuticals Inc (NASDAQ: XFOR) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating on the stock. 7.5%
4/9 X4 Pharmaceuticals to Present and Participate in the Virtual 19th Annual Needham Healthcare Conference 7.3%
12/23 X4 Pharmaceuticals Inc (NASDAQ: XFOR) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $20.00 price target on the stock. 5.8%
11/10 X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.7%
2/28 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock. 5.3%
TOP News Decliners
3/20
Form 8-K X4 Pharmaceuticals, Inc For: Mar 18
-29.5%
4/1 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -18.3%
3/17 Form 8-K X4 Pharmaceuticals, Inc For: Mar 13 -17.5%
11/26 X4 Pharmaceuticals Prices $65 Million Public Offering of Common Stock and Class B Warrants -16.8%
3/26 X4 Pharmaceuticals Inc (NASDAQ: XFOR) had its price target lowered by analysts at Citigroup Inc from $16.00 to $15.00. They now have a "buy" rating on the stock. -15.8%
9/20 Form 8-K X4 Pharmaceuticals, Inc For: Sep 18 -12.4%
3/13 Form S-8 X4 Pharmaceuticals, Inc -12.1%
5/17 Form 8-K/A X4 Pharmaceuticals, Inc For: Mar 29 -9.0%
9/14 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.5%
5/15 X4 Pharmaceuticals and The Leukemia & Lymphoma Society Announce Collaboration to Advance Development of Mavorixafor in Waldenström’s Macroglobulinemia -7.4%
4/1 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -18.3%
3/17 Form 8-K X4 Pharmaceuticals, Inc For: Mar 13 -17.5%
11/26 X4 Pharmaceuticals Prices $65 Million Public Offering of Common Stock and Class B Warrants -16.8%
3/26 X4 Pharmaceuticals Inc (NASDAQ: XFOR) had its price target lowered by analysts at Citigroup Inc from $16.00 to $15.00. They now have a "buy" rating on the stock. -15.8%
9/20 Form 8-K X4 Pharmaceuticals, Inc For: Sep 18 -12.4%
3/13 Form S-8 X4 Pharmaceuticals, Inc -12.1%
5/17 Form 8-K/A X4 Pharmaceuticals, Inc For: Mar 29 -9.0%
9/14 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.5%
5/15 X4 Pharmaceuticals and The Leukemia & Lymphoma Society Announce Collaboration to Advance Development of Mavorixafor in Waldenström’s Macroglobulinemia -7.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: